Chrysalis is pioneering the use of natural regenerative peptides to restore vascular function and activate normal stem cell populations where they exist in the body to accelerate tissue repair and prevent damaging effects of trauma, disease, ischemia, and radiation exposure
Solution for Radiation Induced Tissue Damage
Development of drugs to selectively reduce radiotherapy-induced normal tissue damage may improve post-therapy quality of life and save lives.
Solution for Nuclear Radiation Exposure
A single TP508 injection 24 hours after a lethal dose of whole body radiation significantly increases survival and reduces delayed effects of radiation.
TP508 Peptide Technology
The TP508 thrombin peptide is released locally following vascular injury to initiate cellular regenerative processes that lead to revascularization, stem cell activation, and tissue repair.
Chrysalis BioTherapeutics is developing a “next generation” therapeutic approach that harnesses the body’s natural regenerative signals to protect and activate endogenous progenitor stem cells.
Latest Press Releases
Chrysalis BioTherapeutics Receives Funding from the National Institutes of Health for COVID-19 Therapeutic Development
GALVESTON, Texas–(BUSINESS WIRE)–Chrysalis BioTherapeutics, Inc., a clinical-stage biotechnology company developing regenerative drugs for acute organ injury caused by radiation exposure, announced today that the National
GALVESTON A drug developed by an independent biotech firm headquartered in Galveston will be tested for clinical application to problems related to COVID-19, thanks to
GALVESTON, Texas, Aug. 27, 2019 /PRNewswire/ — Chrysalis BioTherapeutics, Inc. today announced that the Biomedical Advanced Research and Development Authority (BARDA), an agency of the US government’s Department